Do ambulatory-use Platelet-Rich Plasma (PRP) concentrates present risks?
Platelet-Rich Plasma (PRP) concentrates have been widely used in the past decade as a complement to tissue regeneration procedures. The authors who have clinically used PRP refer no risk of infection, disease transmission, or undesirable effects. Nevertheless, there have been reports on the over-expression of growth factors (GFs) and their receptors related to tumour and dysplastic tissues. This has led to evaluation of the possible coincidences between carcinogenesis and the mitogenic pathways employed by GFs. The present study provides a review of the literature on the possible effects of the therapeutic uses of GFs (including PRP) in relation to carcinogenesis, their influence upon tissues with epithelial dysplasia or oral carcinoma, and their relation to tumour growth and infiltration.
Martinez-Gonzalez
J M
JM
Cirugia Bucal Universidad Complutense Madrid, Spain. jmargo@odon.ucm.es
Cano-Sanchez
J
J
Gonzalo-Lafuente
J C
JC
Campo-Trapero
J
J
Esparza-Gomez
G
G
Seoane
J
J
D000553:Ambulatory Care; D002294:Carcinoma, Squamous Cell / Q000209:etiology; D004848:Epithelium / Q000473:pathology; D006801:Humans; D009055:Mouth / Q000473:pathology; D009062:Mouth Neoplasms / Q000209:etiology; D017713:Platelet Transfusion / Q000009:adverse effects*; D010982:Platelet-Derived Growth Factor / Q000096:biosynthesis; D012307:Risk Factors
D010982:Platelet-Derived Growth Factor